RSS  JOBS   SITE MAP 
 HOME 
PHARMA
BIO TECHNOLOGY
MEDICAL TECHNOLOGY
 RESOURCE CENTER 
 NEWSLETTER 
 DIGITAL MAGAZINE 
  Thursday, February 9, 2012 SEARCH     
 
BIO AUSTRALIA
BIO CHINA
BIO INDIA
BIO INDONESIA
BIO JAPAN
BIO KOREA
BIO MALAYSIA
BIO NEW ZEALAND
BIO PHILIPPINES
BIO SINGAPORE
BIO TAIWAN
BIO THAILAND
 
TRENDS & ANALYSIS
Global insulin pumps market to reach $1.2 billion by 2017
The global insulin pumps market was valued at $724.3 million in 2010, and is forecast to grow at a compound annual growth rate of 7.9 percent to reach $1.2 billion in 2017
JE vaccine: Hope on the anvil
Manasi Vaidya
Repeated immunization efforts have not yielded expected results, and as Indian companies make a foray into production of the JE vaccine, there is hope for improvement in the situation
TODAY'S NEWS
  Hitachi Aloka Medical introduces diagnostic ultrasound system
  Advinus Therapeutics, CGH initiate R&D collaboration
  BioAsia 2012 from Feb 9
  Avesthagen signs MOU with Japanese Consortium
  Roche disappointed by Illumina's action
  Siemens partners with ViiV Healthcare, Tocagen
 
Advertisement
 
Digital Mag

Issue: Jan 2012
Current Issue
View / Download
Top Story
Diabetes epidemic on the rise
 
 
 
Get the latest news on life sciences in your mail box
Name
E-Mail Id
 
 
Advertisement

 

TRENDS & ANALYSIS
 
Renaissance in genomics with next generation sequencing
Next Generation Sequencing (NGS) is currently the biggest buzzword in the field of genomics
 
Global insulin pumps market to reach $1.2 billion by 2017
The global insulin pumps market was valued at $724.3 million in 2010, and is forecast to grow at a compound annual growth rate of 7.9 percent to reach $1.2 billion in 2017
 
JE vaccine: Hope on the anvil
Repeated immunization efforts have not yielded expected results, and as Indian companies make a foray into production of the JE vaccine, there is hope for improvement in the situation
 
Asian CMOs: A time to expand operations
Asian companies are still reluctant to widen their dialogue with Western companies. They need to further enhance their manufacturing capacity, infrastructure and project delivery to meet the growing demands
 
Asia Pacific: Trends in Type 2 diabetes and obesity biomarkers
Whilst type 2 diabetes and obesity are traditionally diseases of European and American nations, Asia is facing an increasing disease prevalence and a potential healthcare crisis
 
Biocon posts a strong 17% YoY growth in H1FY12
Biocon announced its earnings for the half year ending, here in Bangalore. It recorded revenues at Rs 978 crores with EBITDA at Rs 282 crores and PAT at Rs 156 crores
 
3SBio focuses on flagship product
Epiao has been ranked as the top recombinant human erythropoietin (EPO) since 2002, in terms of units sold and revenue earned
 
Cephalon has a business model based on acquisitions
Cephalon has over 150 products in almost 100 countries, generating revenue worth $2.8 billion in 2010. Furthermore, 13 products of Cephalon are currently undergoing over 65 clinical trials
 
Lupin walking tall with hybrid business model
Following hybrid business model, Lupin was able to garner a revenue of more than $1.3 billion, with 86 percent contribution from formulation and 14 percent contribution from APIs
 
Samsung Biologics adopts flexible business model to jump to biosimilars
Sensing the opportunities in biosimilars, Samsung made a strategic decision to join hands with Quintiles, that has vast experience in the worldwide market in contract research
More
 
Advertisement











 
   
 
Google
BioSpectrumAsia.com BioSpectrumIndia.com Web

About BioSpectrum | How to Advertise | Jobs at BioSpectrum | Jobs at CyberMedia | Contact Us | Privacy Statement



CyberMedia Network Websites


[Voice&Data]  [PCQuest]  [CIOL]  [Dataquest]  [Living Digital]  [IDC India]
[DQ Channels]  [The DQweek]  [DARE]  
[CyberMedia Events] [CyberMedia Digital]  [Cyber Astro]  [CyberMedia India]  [Global Services]  [BioSpectrum]

 
Copyrights are reserved for BioSpectrum ; Designed by : Altered Black